Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection

Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016

“…In the majority of patients in the TMZ + RT group, their initial course of radiotherapy was delivered with TMZ; however, room for additional radiation was considered in 2 cases. Prolonged tumour control following combination TMZ and radiotherapy in APT has also been suggested by others (13,33); however, it should be pointed out that no studies have compared TMZ monotherapy to TMZ + RT in a randomised design.…”

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

“…The tumour had recurred after RT, except in 3 patients who received TMZ concomitantly with RT or one month thereafter. In a recent published case, a patient with a pituitary carcinoma treated with TMZ + bevacizumab concurrent with RT, and subsequently with TMZ alone for an additional 12 cycles, complete regression was achieved and sustained five years (128).…”

Is MGMT the best marker to predict response of temozolomide in aggressive pituitary tumors? Alternative markers and prospective treatment modalities

“…The drug was recently applied either as monotherapy or in combination with TMZ in two patients, one of them with a clinically aggressive silent corticotroph adenoma subtype 2, the other with a functioning corticotroph carcinoma immunoreactive for VEGF. Bevacizumab stopped tumor progression for 26 months and 5 years of follow-up, respectively [28,29]. It should be noted that VEGF expression predicts a favorable outcome of treatment.…”